Cell Bioengines, Inc

About Us: Cell BioEngines is a US-based clinical-stage biotechnology company pioneering off-the-shelf, allogeneic cell therapies. Leveraging blood stem cells from cords of highly compatible super-donors and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical program is currently in a multi-center Phase 1b/2a trial for relapsed blood cancer patients including CAR-T cell therapy. The company emphasizes a robust, closed-loop scalable manufacturing in partnership with Miltenyi Biotec, has now entered strategic collaboration with NVIDIA to model donor HLA-screening and population aligned biobank strategy. The pipeline also includes Type 1 dendritic cell therapy for solid tumors and other first-/best-in-class immunotherapy programs. For more information, visit and follow us on